Floatz logo

Interleukin-15

Lung Carcinoma

Essen Biotechprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
Etoposide
SystImmune Inc.
Phase 3BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Carboplatin
SystImmune Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Interleukin-15 is also rated in:

acute myeloid leukemiaDormant
B
Indicative · Phase 2
57 / 100
View asset →
leukemiaActive
CC
Indicative · Phase 1/2
47 / 100
View asset →
breast cancerActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →